The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer
Open accessAbstract
Rigorous quality control steps, termed checkpoints, tightly regulate progression through the cell cycle. DNA-damaging chemotherapy and radiation activate functional cellular checkpoints. These checkpoints can facilitate DNA repair and promote cell death in unrepaired cells. There are at least three DNA damage checkpoints - at G1/S, S, and G2/M - as well as a mitotic spindle checkpoint. Most cancer cells harbour mutations in tumour suppressors and/or oncogenes, which impair certain cell checkpoints. Inhibiting the remaining cell checkpoints - particularly after exposure of cancer cells to chemotherapy and/or radiation - allows cell death, a strategy now being employed in cancer therapeutics. With our increasing knowledge of cell cycle regulation, many compounds have been developed to inhibit specific checkpoint components, particularly at the G2/M transition. One such target is checkpoint kinase-1 (Chk1). We review here the molecular framework of the cell cycle, the rationale for targeting Chk1, the preclinical concepts related to the development of Chk1 inhibitors, and the efficacy and safety results from Chk1 inhibitors now in phase I/II trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints
Sancar, A., Lindsey-Boltz, L. A., Ünsal-Kaçmaz, K., & Linn, S. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073723 · Cited by 3,317
Sensing DNA Damage Through ATRIP Recognition of RPA-ssDNA Complexes
Zou, L., & Elledge, S. J. (2003) · Science · doi:10.1126/science.1083430 · Cited by 2,693
Liu, Q., Guntuku, S., Cui, X.-S., Matsuoka, S., Cortez, D., Tamai, K., Luo, G., Carattini-Rivera, S., DeMayo, F., Bradley, A., et al. (2000) · Genes & Development · doi:10.1101/gad.14.12.1448 · Cited by 1,625
Regulation of the G2/M transition by p53
Taylor, W. R., & Stark, G. R. (2001) · Oncogene · doi:10.1038/sj.onc.1204252 · Cited by 1,559
G1 cell-cycle control and cancer
Massagué, J. (2004) · Nature · doi:10.1038/nature03094 · Cited by 1,224
Hickson, I., Zhao, Y., Richardson, C. J., Green, S. J., Martin, N. M. B., Orr, A. I., Reaper, P. M., Jackson, S. P., Curtin, N. J., & Smith, G. C. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2727 · Cited by 1,220
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
Rapid Destruction of Human Cdc25A in Response to DNA Damage
Mailand, N., Falck, J., Lukas, C., Syljuåsen, R. G., Welcker, M., Bartek, J., & Lukas, J. (2000) · Science · doi:10.1126/science.288.5470.1425 · Cited by 787
Checking on DNA damage in S phase
Bartek, J., Lukas, C., & Lukas, J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1493 · Cited by 758
Essential role of BETA2/NeuroD1 in development of the vestibular and auditory systems
Liu, M., Pereira, F. A., Price, S. D., Chu, M.-J., Shope, C., Himes, D., Eatock, R. A., Brownell, W. E., Lysakowski, A., & Tsai, M.-J. (2000) · Genes & Development · doi:10.1101/gad.840500 · Cited by 625
Reinhardt, H. C., Aslanian, A. S., Lees, J. A., & Yaffe, M. B. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.024 · Cited by 596
Regulation of ATR substrate selection by Rad17-dependent loading of Rad9 complexes onto chromatin
Zou, L., Cortez, D., & Elledge, S. J. (2002) · Genes & Development · doi:10.1101/gad.950302 · Cited by 498
Zhao, H., Watkins, J. L., & Piwnica-Worms, H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182557299 · Cited by 461
Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.
Shah, M. A., & Schwartz, G. K. (2001) · PubMed · Cited by 450
Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription
Takai, H., Naka, K., Okada, Y., Watanabe, M., Harada, N., Saito, S., Anderson, C. W., Appella, E., Nakanishi, M., Suzuki, H., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf506 · Cited by 436
Manke, I. A., Nguyen, A., Lim, D., Stewart, M. Q., Elia, A. E. H., & Yaffe, M. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.11.021 · Cited by 416
The when and wheres of CDC25 phosphatases
Boutros, R., Dozier, C., & Ducommun, B. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.02.003 · Cited by 414
Chk2 kinase — a busy messenger
Bartek, J., Falck, J., & Lukas, J. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35103059 · Cited by 403
The DNA damage-dependent intra–S phase checkpoint is regulated by parallel pathways
Falck, J., Petrini, J. H. J., Williams, B. R., Lukas, J., & Bartek, J. (2002) · Nature Genetics · doi:10.1038/ng845 · Cited by 392
Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents
Xiao, Z., Chen, Z., Gunasekera, A. H., Sowin, T. J., Rosenberg, S. H., Fesik, S., & Zhang, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300229200 · Cited by 388
G2 checkpoint abrogators as anticancer drugs
Kawabe, T. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.513.3.4 · Cited by 377
Gatei, M., Sloper, K., Sörensen, C., Syljuäsen, R., Falck, J., Hobson, K., Savage, K., Lukas, J., Zhou, B.-B., Bartek, J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210862200 · Cited by 300
Mechanism by which caffeine potentiates lethality of nitrogen mustard.
Lau, C. C., & Pardee, A. B. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.9.2942 · Cited by 291
The MRN complex: coordinating and mediating the response to broken chromosomes
van den Bosch, M., Bree, R. T., & Lowndes, N. F. (2003) · The EMBO Reports · doi:10.1038/sj.embor.embor925 · Cited by 289
Chk1 Is Required for Spindle Checkpoint Function
Zachos, G., Black, E. J., Walker, M., Scott, M. T., Vagnarelli, P., Earnshaw, W. C., & Gillespie, D. A. F. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.01.003 · Cited by 236
Claspin Operates Downstream of TopBP1 To Direct ATR Signaling towards Chk1 Activation
Liu, S., Bekker-Jensen, S., Mailand, N., Lukas, C., Bartek, J., & Lukas, J. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00492-06 · Cited by 182
Hsp90 Inhibition Depletes Chk1 and Sensitizes Tumor Cells to Replication Stress
Arlander, S. J. H., Eapen, A. K., Vroman, B. T., McDonald, R. J., Toft, D. O., & Karnitz, L. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m309054200 · Cited by 169
Matthews, D. J., Yakes, M., Chen, J., Tadano, M., Bornheim, L. M., Clary, D. O., Tai, A., Wagner, J. M., Miller, N., Kim, Y. D., et al. (2007) · Cell Cycle · doi:10.4161/cc.6.1.3699 · Cited by 153
Tse, A. N., Rendahl, K. G., Sheikh, T. N., Cheema, H., Aardalen, K., Embry, M. G., Ma, S., Moler, E. J., Ni, Z., de Menezes, D. E. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1424 · Cited by 153
Targeting Checkpoint Kinase 1 in Cancer Therapeutics
Tse, A. N., Carvajal, R. D., & Schwartz, G. K. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2793 · Cited by 148
Jack, M. T., Woo, R. A., Hirao, A., Cheung, A., Mak, T. W., & Lee, P. W. K. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152053599 · Cited by 140
Lukas, C., Bártková, J., Latella, L., Falck, J., Mailand, N., Schroeder, T., Sehested, M., Lukáš, J., & Bártek, J. (2001) · PubMed · Cited by 133
Watrin, E., & Peters, J. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.06.024 · Cited by 117
Kortmansky, J. S., Shah, M. A., Kaubisch, A., Weyerbacher, A. R., Yi, S., Tong, W. P., Sowers, R. S., Gönen, M., O'Reilly, E. M., Kemeny, N. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.116 · Cited by 112
Xiao, Z., Xue, J., Sowin, T. J., & Zhang, H. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0077 · Cited by 110
Chen, Z., Xiao, Z., Chen, J., Ng, S., Sowin, T. J., Sham, H. L., Rosenberg, S. H., Fesik, S., & Zhang, H. (2003) · PubMed · Cited by 110
Tao, Z., Wang, L., Stewart, K. D., Chen, Z., Gu, W., Bui, M.-H., Merta, P. J., Zhang, H., Kovar, P. J., Johnson, E. F., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061247v · Cited by 84
Hashimoto, O., Shinkawa, M., Torimura, T., Nakamura, T., Selvendiran, K., Sakamoto, M., Koga, H., Ueno, T., & Sata, M. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-292 · Cited by 83
Conchon, E., Anizon, F., Aboab, B., & Prudhomme, M. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070664k · Cited by 71
Sha, S.-K., Sato, T., Kobayashi, H., Ishigaki, M., Yamamoto, S., Sato, H., Takada, A., Nakajyo, S., Mochizuki, Y., Friedman, J. M., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0371 · Cited by 52
Checkpoint Mediators: Relaying Signals from DNA Strand Breaks
Canman, C. E. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00410-x · Cited by 47
Tao, Z., Li, G., Tong, Y., Chen, Z., Merta, P. J., Kovar, P. J., Zhang, H., Rosenberg, S. H., Sham, H. L., Sowin, T. J., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.027 · Cited by 23
Cytosine arabinoside plus cisplatin and other drugs as chemotherapy for gliomas.
Stewart, D. J., Hugenholtz, H., DaSilva, V. F., Benoit, B. G., Richard, M. T., Russell, N. A., Maroun, J. A., & Verma, S. (1987) · PubMed · Cited by 11
Cited by
Strategies to improve radiotherapy with targeted drugs
Begg, A. C., Stewart, F. A., & Vens, C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3007 · Cited by 1,118
Mitotic catastrophe: a mechanism for avoiding genomic instability
Vitale, I., Galluzzi, L., Castedo, M., & Kroemer, G. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3115 · Cited by 834
Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma
Clark, D. J., Dhanasekaran, S. M., Petralia, F., Pan, J., Song, X., Hu, Y., da Veiga Leprevost, F., Reva, B., Lih, T.-S. M., Chang, H.-Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.007 · Cited by 730
Lovejoy, C. A., Li, W., Reisenweber, S., Thongthip, S., Bruno, J., de Lange, T., De, S., Petrini, J. H. J., Sung, P. A., Jasin, M., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002772 · Cited by 629
“Indeed, G2/M checkpoint inhibitors to enhance efficacy of clastogenic therapies are currently being developed and evaluated in clinical trials [54].”
BackgroundIonizing Radiation-Induced DNA Damage, Response, and Repair
Santivasi, W. L., & Xia, F. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5668 · Cited by 593
Metadata
- Authors
- Bucher, N., & Britten, C. D.
- Venue
- British Journal of Cancer
- Published
- 2008-01-29
- Volume
- 98
- Issue
- 3
- Pages
- 523-528
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2023942118
- Cited by
- 349
- References
- 45
- FWCI
- 13.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.